Adverse side effects to biological agents

Drug Hypersensitivity

Volumn , Issue , 2007, Pages 151-165

  Pichler Prof Dr , Werner J ^a   Campi, Paolo ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882124318     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000104198     Document Type: Chapter

References (63)

1. Abbas AK, Lichtman AH: Cellular and molecular immunology, ed 5. Philadelphia, Saunders, 2003.
2. Weber RW: Adverse reactions to biological modifiers. Curr Opin Allergy Clin Immunol 2004; 4: 277-283.
3. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK: Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23: 483-507.
4. Hoigne R, Schlumberger HP, Vervloet D, Zoppi M: Epidemiology of allergic drug reactions. Monogr Allergy 1993; 31: 147-170.
5. Coombs PRA GP: Classification of allergic reactions responsible for clinical hypersensitivity and disease; in Gell RRA (ed): Clinical Aspects of Immunology. Oxford, Oxford University Press, 1968, pp 575-596.
6. Pichler WJ: Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683-693.
7. Waugh J, Perry CM: Anakinra: a review of its use in the management of rheumatoid arthritis. BioDrugs 2005; 19: 189-202.
8. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
9. Vasquez EM, Fabrega AJ, Pollak R: OKT3-induced cytokine-release syndrome:occurrence beyond the second dose and association with rejection severity. Transplant Proc 1995; 27: 873-874.
10. Suntharalingam G, Perry MR, Ward S, et al: Cytokine storm in a phase 1 trial of the anti CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
11. Pichler WJ: Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2:301-305.
12. Schrodt BJ, Kulp-Shorten CL, Callen JP: Necrotizing vasculitis of the skin and uterine cervix associated with minocycline therapy for acne vulgaris. South Med J 1999; 92: 502-504.
13. Chatenoud L: Immunologic monitoring during OKT3 therapy. Clin Transplant 1993; 7: 422-430.
14. Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N: Epoetinassociated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 2005; 20(suppl 3):33-40.
15. Baert F, Noman M, Vermeire S, et al: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608.
16. Lipsky PE, van der Heijde DM, St Clair EW, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
17. Abramowicz D, Crusiaux A, Goldman M: Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 1992; 327: 736.
18. Han PD, Cohen RD: Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 2004; 64: 1767-1777.
19. Arimura K, Arima N, Ohtsubo H, et al: Severe autoimmune thrombocytopenic purpura during interferon-αtherapy for chronic myelogenous leukemia.Acta Haematol 2004; 112: 217-218.
20. Werth VP, Levinson AI: Etanerceptinduced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. Arch Dermatol 2001; 137: 953-955.
21. Kassiotis G, Kollias G: TNF and receptors in organ-specific autoimmune disease: multi layered functioning mirrored in animal models. J Clin Invest 2001; 107: 1507-1508.
22. Vermeire S, Noman M, Van Assche G, et al: Autoimmunity associated with antitumor necrosis factor-αtreatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125: 32-39.
23. Banchereau J, Pascual V, Palucka AK: Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004; 20: 539-550.
24. Hershberger RE, Starling RC, Eisen HJ, et al: Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352: 2705-2713.
25. Wellington K, Perry CM: Efalizumab.Am J Clin Dermatol 2005; 6: 113-120.
26. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD: Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.
27. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T-lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377.
28. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O: Anti-TNF-α-induced systemic lupus syndrome. Clin Rheumatol 2003; 22: 56-61.
29. Seckin D, Durusoy C, Sahin S: Concomitant vitiligo and psoriasis in a patient treated with interferon-alfa-2a for chronic hepatitis B infection. Pediatr Dermatol 2004; 21: 577-579.
30. Day R: Adverse reactions to TNF-αinhibitors in rheumatoid arthritis. Lancet 2002; 359: 540-541.
31. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E: Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-αin the normal palmar eccrine sweat duct? Br J Dermatol 2005; 153:1243-1244.
32. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM: Adverse skin reactions to anti-TNF-αmonoclonal antibody therapy.Dermatology 2003; 206: 388-390.
33. Chan JL, Davis-Reed L, Kimball AB: Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol 2004; 3: 315-318.
34. Menon Y, Cucurull E, Reisin E, Espinoza LR: Interferon-α-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci 2004; 328: 173-175.
35. Solans R, Bosch JA, Esteban I, Vilardell M: Systemic sclerosis developing in association with the use of interferon-α therapy for chronic viral hepatitis. Clin Exp Rheumatol 2004; 22: 625-628.
36. Niewold TB, Swedler WI: Systemic lupus erythematosus arising during interferon-α therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24: 178-181.
37. Boz C, Ozmenoglu M, Aktoz G, Velioglu S, Alioglu Z: Guillain-BarrÉ syndrome during treatment with interferon-α for hepatitis B. J Clin Neurosci 2004; 11: 523-525.
38. Doi F, Kakizaki S, Takagi H, et al: Long-term outcome of interferon-α -induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int 2005; 25: 242-246.
39. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A: Tolllike receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204: 27-42.
40. Perez-Soler R, Saltz L: Cutaneous adverse effects with HER1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol 2005; 23: 5235-5246.
41. Danese S, Fiocchi C: Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol 2005; 25: 103-121.
42. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-811.
43. Kasahara A, Hiraide A, Tomita N, et al: Vogt-Koyanagi-Harada disease occurring during interferon-α therapy for chronic hepatitis C. J Gastroenterol 2004; 39: 1106-1109.
44. Bagheri H, Fouladi A, Barange K, et al: Follow-up of adverse drug reactions from peginterferon-alfa-2b-ribavirin therapy. Pharmacotherapy 2004; 24:1546-1553.
45. Chamberlain AJ, Poon E: Cutaneous reactions to interferon and ribavirin. Intern Med J 2004; 34: 519.
46. Panwar P, Iznaga-Escobar N, Mishra P,et al: Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody or egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther 2005; 4.
47. Brown DL, Login IS, Borish L, Powers PL: An urticarial IgE-mediated reaction to interferon-Β 1b Neurology 2001; 56: 1416-1417.
48. Corona T, Leon C, Ostrosky-Zeichner L: Severe anaphylaxis with recombinant interferon-Β . Neurology 1999; 52:425.
49. Puchner TC, Kugathasan S, Kelly KJ, Binion DG: Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7: 34-37.
50. O'Connor M, Buchman A, Marshall G: Anaphylaxis-like reaction to infliximab infliximab in a patient with Crohn's disease.Dig Dis Sci 2002; 47: 1323-1325.
51. Hyams JS, Markowitz J, Wyllie R: Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137: 192-196.
52. Soykan I, Ertan C, Ozden A: Severe anaphylactic reaction to infliximab: report of a case. Am J Gastroenterol 2000; 95: 2395-2396.
53. Diamanti A, Castro M, Papadatou B, Ferretti F, Gambarara M: Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease. J Pediatr 2002; 140: 636-637.
54. Lobel EZ, Korelitz BI, Warman JI: Red man syndrome and infliximab. J Clin Gastroenterol 2003; 36: 186.
55. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS: Severe anaphylactic reaction to infliximab: successful treatment with adalimumab -report of a case. Eur J Gastroenterol Hepatol 2004; 16: 627-630.
56. Youdim A, Vasiliauskas EA, Targan SR, et al: A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10: 333-338.
57. Lelong J, Duburque C, Fournier C, et al: Desensitisation to infliximab in patients with Crohn's disease (in French). Rev Mal Respir 2005; 22: 239-246.
58. Domm A: A patient's reaction to infliximab. Ann Allergy Asthma Immunol 2003; 90: 298-301.
59. Chavez-Lopez MA, Delgado-Villafana J, Gallaga A, Huerta-Yanez G: Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol (Madr) 2005; 33: 291-292.
60. Leonard PA, Woodside KJ, Gugliuzza KK, Sur S, Daller JA: Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. Transplantation 2002; 74: 1697-1700.
61. Baudouin V, Crusiaux A, Haddad E, et al: Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003; 76: 459-463.
62. Melamed J, Stahlman JE: Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin). J Allergy Clin Immunol 2002; 110: 813-814.
63. Tada K, Ito Y, Hatake K, et al: Severe infusion reaction induced by trastuzumab: a case report. Breast Cancer 2003; 10: 167-169.